Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.04 Billion USD | -349.57% |
| 2023 | -232 Million USD | -146.49% |
| 2022 | 499 Million USD | -14.7% |
| 2021 | 585 Million USD | 238.15% |
| 2020 | 173 Million USD | 25.91% |
| 2019 | 137.4 Million USD | 64.35% |
| 2018 | 83.6 Million USD | -23.86% |
| 2017 | 109.8 Million USD | -1.52% |
| 2016 | 111.5 Million USD | -47.46% |
| 2015 | 212.2 Million USD | 1209.88% |
| 2014 | 16.2 Million USD | 134.69% |
| 2013 | -46.7 Million USD | -91.39% |
| 2012 | -24.4 Million USD | 54.81% |
| 2011 | -54 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -206 Million USD | 71.19% |
| 2024 FY | -1.04 Billion USD | -349.57% |
| 2024 Q3 | -101 Million USD | 50.97% |
| 2024 Q4 | 23 Million USD | 122.77% |
| 2024 Q1 | -715 Million USD | -731.4% |
| 2023 Q4 | -86 Million USD | 62.11% |
| 2023 Q3 | -227 Million USD | -380.25% |
| 2023 Q2 | 81 Million USD | 0.0% |
| 2023 FY | -232 Million USD | -146.49% |
| 2023 Q1 | - USD | -100.0% |
| 2022 Q3 | 141 Million USD | 51.61% |
| 2022 FY | 499 Million USD | -14.7% |
| 2022 Q1 | 84 Million USD | -50.27% |
| 2022 Q4 | 187 Million USD | 32.62% |
| 2022 Q2 | 93 Million USD | 10.71% |
| 2021 Q4 | 168.9 Million USD | -22.17% |
| 2021 FY | 585 Million USD | 238.15% |
| 2021 Q3 | 217 Million USD | 181.82% |
| 2021 Q1 | 69 Million USD | -48.62% |
| 2021 Q2 | 77 Million USD | 11.59% |
| 2020 FY | 173 Million USD | 25.91% |
| 2020 Q3 | 20.9 Million USD | -39.07% |
| 2020 Q2 | 34.3 Million USD | 34200.0% |
| 2020 Q4 | 134.3 Million USD | 542.58% |
| 2020 Q1 | 100 Thousand USD | -99.85% |
| 2019 FY | 137.4 Million USD | 64.35% |
| 2019 Q1 | -14.4 Million USD | -117.41% |
| 2019 Q2 | 49 Million USD | 440.28% |
| 2019 Q3 | 31.7 Million USD | -35.31% |
| 2019 Q4 | 65.7 Million USD | 107.26% |
| 2018 Q1 | 3.8 Million USD | -93.85% |
| 2018 Q4 | 82.7 Million USD | 335.26% |
| 2018 Q3 | 19 Million USD | 186.76% |
| 2018 Q2 | -21.9 Million USD | -676.32% |
| 2018 FY | 83.6 Million USD | -23.86% |
| 2017 Q2 | 17.4 Million USD | 278.26% |
| 2017 Q3 | 26 Million USD | 49.43% |
| 2017 Q4 | 61.8 Million USD | 137.69% |
| 2017 FY | 109.8 Million USD | -1.52% |
| 2017 Q1 | 4.6 Million USD | -92.57% |
| 2016 FY | 111.5 Million USD | -47.46% |
| 2016 Q2 | 30.7 Million USD | 237.36% |
| 2016 Q4 | 61.9 Million USD | 478.5% |
| 2016 Q1 | 9.1 Million USD | -94.08% |
| 2016 Q3 | 10.7 Million USD | -65.15% |
| 2015 FY | 212.2 Million USD | 1209.88% |
| 2015 Q4 | 153.7 Million USD | 387.94% |
| 2015 Q1 | -19.5 Million USD | -171.69% |
| 2015 Q3 | 31.5 Million USD | -32.26% |
| 2015 Q2 | 46.5 Million USD | 338.46% |
| 2014 Q2 | -19.2 Million USD | -1380.0% |
| 2014 FY | 16.2 Million USD | 134.69% |
| 2014 Q3 | 6.7 Million USD | 134.9% |
| 2014 Q1 | 1.5 Million USD | -92.19% |
| 2014 Q4 | 27.2 Million USD | 305.97% |
| 2013 Q3 | -18.8 Million USD | 31.39% |
| 2013 Q4 | 19.2 Million USD | 202.13% |
| 2013 FY | -46.7 Million USD | -91.39% |
| 2013 Q1 | -19.7 Million USD | 0.0% |
| 2013 Q2 | -27.4 Million USD | -39.09% |
| 2012 FY | -24.4 Million USD | 54.81% |
| 2011 FY | -54 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | -83.99 Million USD | -1141.77% |
| Bausch Health Companies Inc. | -592 Million USD | -76.182% |
| Emergent BioSolutions Inc. | -760.5 Million USD | -37.147% |
| Elanco Animal Health Incorporated | -1.23 Billion USD | 15.272% |
| Perrigo Company plc | -12.7 Million USD | -8112.598% |
| Teva Pharmaceutical Industries Limited | -559 Million USD | -86.583% |
| Zoetis Inc. | 2.34 Billion USD | 144.497% |